IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

BIGGIOGGERO, MARTINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.249
EU - Europa 1.208
AS - Asia 534
SA - Sud America 24
OC - Oceania 10
AF - Africa 6
Continente sconosciuto - Info sul continente non disponibili 4
Totale 3.035
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.192
GB - Regno Unito 347
CN - Cina 250
IT - Italia 232
SE - Svezia 172
DE - Germania 137
IE - Irlanda 73
IN - India 53
CA - Canada 52
FR - Francia 51
RU - Federazione Russa 49
TR - Turchia 42
KR - Corea 41
JP - Giappone 32
HK - Hong Kong 29
UA - Ucraina 29
FI - Finlandia 28
SG - Singapore 26
NL - Olanda 18
BE - Belgio 16
EU - Europa 14
TW - Taiwan 13
CO - Colombia 12
ID - Indonesia 12
ES - Italia 11
VN - Vietnam 9
AU - Australia 8
DK - Danimarca 8
IR - Iran 7
PL - Polonia 7
GR - Grecia 6
BR - Brasile 5
MX - Messico 5
UZ - Uzbekistan 5
NO - Norvegia 4
RO - Romania 4
AP - ???statistics.table.value.countryCode.AP??? 3
AT - Austria 3
CL - Cile 3
EC - Ecuador 3
PH - Filippine 3
TH - Thailandia 3
CH - Svizzera 2
CZ - Repubblica Ceca 2
HU - Ungheria 2
IL - Israele 2
LT - Lituania 2
MD - Moldavia 2
NZ - Nuova Zelanda 2
PT - Portogallo 2
ZA - Sudafrica 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BD - Bangladesh 1
BG - Bulgaria 1
CY - Cipro 1
DZ - Algeria 1
EG - Egitto 1
ET - Etiopia 1
KZ - Kazakistan 1
LB - Libano 1
LK - Sri Lanka 1
MY - Malesia 1
PE - Perù 1
SA - Arabia Saudita 1
SC - Seychelles 1
Totale 3.049
Salva come PNG Salva come JPEG
Città #
Southend 302
Chandler 275
Milan 103
Princeton 83
Seattle 75
Dublin 72
Ann Arbor 53
Fairfield 51
Wilmington 49
Ashburn 48
Beijing 48
Dearborn 44
Frankfurt am Main 42
Toronto 37
Grafing 34
Bengaluru 27
Woodbridge 27
Hong Kong 24
Cambridge 23
New York 23
Houston 22
Redmond 22
Des Moines 18
Mountain View 18
Nanjing 16
Boardman 15
Brussels 14
Jacksonville 14
Sunnyvale 14
San Diego 13
Bologna 12
Guangzhou 12
Redwood City 12
Shanghai 12
Medford 11
Tokyo 11
Bogotá 10
Hebei 10
Phoenix 10
Sakarya 10
Shenyang 10
Somerville 10
Andover 9
Istanbul 9
Berlin 8
Helsinki 8
Serra 8
Edinburgh 7
Seoul 7
Changsha 6
Council Bluffs 6
Eitensheim 6
Jinan 6
Madrid 6
Athens 5
Hangzhou 5
Izmir 5
Tashkent 5
Warsaw 5
Annecy 4
Colorado Springs 4
Dong Ket 4
Fremont 4
Hamburg 4
Jiaxing 4
Los Angeles 4
Montreal 4
Nanchang 4
New Delhi 4
Rho 4
Singapore 4
Upper Marlboro 4
Chengdu 3
Chicago 3
Guiyang 3
Jalandhar 3
Kilburn 3
London 3
Melbourne 3
Montespertoli 3
Ottawa 3
Rome 3
Roxbury 3
Stockholm 3
Suizenji 3
Taipei 3
Taizhou 3
Tappahannock 3
Aberdeen 2
Alytus 2
Amsterdam 2
Ansbach 2
Atlanta 2
Auburn Hills 2
Auburn University 2
Bangalore 2
Bergamo 2
Bitonto 2
Bornova 2
Bronx 2
Totale 1.971
Salva come PNG Salva come JPEG
Nome #
Eight-year retention rate of first-line tumor necrosis factor inhibitors in spondyloarthritis : A multi-center retrospective analysis 280
Immune function in children born to mothers with autoimmune diseases and exposed in utero to immunosuppressants 157
Baricitinib for COVID-19: a suitable treatment? 143
IL1 and TNF gene polymorphisms in patients with juvenile idiopathic arthritis treated with TNF inhibitors 139
Clinical management of patients with rheumatoid arthritis during the COVID-19 pandemic 136
Prospectively-followed pregnancies in patients with inflammatory arthritis taking biological drugs : an Italian multicentre study 118
Juvenile idiopathic arthritis in adulthood in a tertiary reference centre 114
Retrospective evaluation of patient profiling and effectiveness of apremilast in an Italian multicentric cohort of psoriatic arthritis patients 110
Cutting-Edge Issues in Coronary Disease and the Primary Antiphospholipid Syndrome 103
Alterations in the immune system of children from mothers treated with immunosuppressive agents during pregnancy 103
Pregnancy outcomes in women exposed to biologic treatment and affected by chronic arthritis 99
Role of antimalarials in COVID-19 : observational data from a cohort of rheumatic patients 99
The challenging definition of naïve patient for biological drug use 92
Relationship between sle susceptibility genes and clinical manifestations in a cohort of patients with primary antiphospholipid syndrome 91
Type I interferon therapy and its role in autoimmunity 89
Osteoporosis 84
The role of biologic agents in damage progression in rheumatoid arthritis: indirect comparison of data coming from randomized clinical trials 82
The geoepidemiology of the antiphospholipid antibody syndrome 82
Arthritis and infections 82
Transforming growth factor beta1 in the pathogenesis of autoimmune congenital complete heart block : lesson from twins and triplets discordant for the disease 75
The comparison of effects of biologic agents on rheumatoid arthritis damage progression is biased by period of enrolment: data from a systematic review and meta-analysis 67
Comment on : Bisphosphonates and osteonecrosis of the jaw 60
Is there really room for anti-rheumatic drugs in the treatment of COVID-19? 55
Standardization of autoantibody testing : a paradigm for serology in rheumatic diseases 53
Immunosuppressant Treatment in Rheumatic Musculoskeletal Diseases Does Not Inhibit Elicitation of Humoral Response to SARS-CoV-2 Infection and Preserves Effector Immune Cell Populations 51
Personalized medicine in rheumatoid arthritis: How immunogenicity impacts use of TNF inhibitors 50
Ultraviolet light exposure is not a requirement for the development of cutaneous neonatal lupus 48
Impact of corticosteroids and immunosuppressive therapies on symptomatic SARS-CoV-2 infection in a large cohort of patients with chronic inflammatory arthritis 42
The Use of Rheumatic Disease Comorbidity Index for Predicting Clinical Response and Retention Rate in a Cohort of Rheumatoid Arthritis Patients Receiving Tumor Necrosis Factor Alpha Inhibitors 42
The Impact of Anti-rheumatic Drugs on the Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Cohort of Patients With Inflammatory Arthritis: The MAINSTREAM Study 41
Sex and Management of Rheumatoid Arthritis 40
Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis 40
The management of first-line biologic therapy failures in rheumatoid arthritis : current practice and future perspectives 38
Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients : Results from the GISEA register 37
The role of concomitant methotrexate dosage and maintenance over time in the therapy of rheumatoid arthritis patients treated with adalimumab or etanercept : Retrospective analysis of a local registry 36
Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations : similarities and differences 34
Spotlight on mavrilimumab for the treatment of rheumatoid arthritis : Evidence to date 31
Tocilizumab in the treatment of rheumatoid arthritis : An evidence-based review and patient selection 30
Sarilumab : patient-reported outcomes in rheumatoid arthritis 28
Retention rate of a second line with a biologic DMARD after failure of a first-line therapy with abatacept, tocilizumab, or rituximab : results from the Italian GISEA registry 26
The role of methotrexate as combination therapy with etanercept in rheumatoid arthritis: Retrospective analysis of a local registry 26
Targeting Granulocyte-Monocyte Colony-Stimulating Factor Signaling in Rheumatoid Arthritis: Future Prospects 25
Is there a need for new thresholds to define remission and low disease activity by disease activity score 28 calculated with C reactive protein? real life data from a local registry 23
A review of the literature analyzing benefits and concerns of infliximab biosimilar CT-P13 for the treatment of rheumatologic diseases: Focus on interchangeability 18
Clinical pharmacology of filgotinib in the treatment of rheumatoid arthritis: current insights 14
Methotrexate for the treatment of rheumatoid arthritis in the biologic era: Still an "anchor" drug? 14
Structural integrity versus radiographic progression in rheumatoid arthritis 8
Ten-Year Drug Survival of Anti-TNF Agents in the Treatment of Inflammatory Arthritides 6
Profile of sarilumab and its potential in the treatment of rheumatoid arthritis 4
Mavrilimumab: a unique insight and update on the current status in the treatment of rheumatoid arthritis 3
Totale 3.268
Salva come PNG Salva come JPEG
Categoria #
all - tutte 9.853
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.853
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201931 0 0 0 0 0 0 0 0 0 5 14 12
2019/2020253 31 17 8 18 11 44 33 9 38 27 10 7
2020/2021400 18 28 25 23 36 35 21 30 75 37 60 12
2021/2022539 25 28 16 9 17 13 36 98 71 54 45 127
2022/2023829 92 102 106 65 99 140 23 40 77 8 52 25
2023/2024394 30 42 24 43 142 38 14 27 12 22 0 0
Totale 3.268